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ORIGINAL ARTICLE
Hematopoietic stem cell transplantation (HSCT)
has been widely applied in the treatment of many
malignant and nonmalignant hematologic disor-
ders, solid tumors, and autoimmune, metabolic
and genetic diseases.1,2 The donor of the stem cell
can be the patient himself (autologous), a human
leukocyte antigen (HLA)-matched sibling or HLA-
matched unrelated donor (allogeneic). Stem cells
can be obtained from cord blood, peripheral blood
stem cells, or bone marrow.3,4 Before the stem cells
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Background/Purpose: To evaluate the ICU mortality rate of mechanically ventilated hematopoietic stem
cell transplantation (HSCT) recipients and to identify the factors that were associated with ICU mortality.
The impact of surgical lung biopsy (SLB) in patients with unexplained pulmonary infiltrates was also evaluated.
Methods: Forty-one mechanically ventilated HSCT recipients admitted to the ICU during the study period
were enrolled. The medical records were reviewed and data at ICU admission were analyzed. Data were
g compared between ICU survivors and nonsurvivors. The pathologic findings of SLB and the resultin
impact on treatment were analyzed.
Results: Eight patients (19.5%) survived the ICU stay, and seven (17%) lived to hospital discharge. The
most common etiologies of ICU mortality included bacterial pneumonia, cytomegalovirus pneumonia,
diffuse alveolar hemorrhage, sepsis, and aspergillosis. The factors associated with higher mortality were
older age when performing HSCT, older age at ICU admission, higher acute physiology and chronic health
evaluation (APACHE) II score, shock, higher respiratory rate, and higher heart rate at the time of ICU
admission. Ten patients underwent SLB which resulted in treatment changes in five of them. Three patients
had complications of SLB and one patient died of complications.
Conclusion: The ICU mortality rate of mechanically ventilated HSCT recipients was high. Factors associated
with ICU mortality were older age, high APACHE II score, presence of shock, and higher respiratory or
heart rate at the time of ICU admission. SLB might provide specific diagnosis in HSCT recipients with unex-
plained pulmonary infiltrates and aid modification of treatment. [J Formos Med Assoc 2007;106(4):295–301]
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are infused, high-dose chemotherapy with or with-
out total body irradiation (TBI) is administrated
as a conditioning regimen, which is a critical ele-
ment in the HSCT procedure. The purposes of
the conditioning regimen are to provide adequate
immunosuppression to prevent rejection of the
transplanted graft and to eradicate the disease for
which the transplantation is being performed.
The conditioning regimen is also responsible for
many of the pulmonary complications which de-
velop in 40–60% of HSCT patients.5–7 Pulmonary
complications are the major risk factors for respira-
tory failure in HSCT recipients. We retrospectively
evaluated the ICU mortality of HSCT patients
who were mechanically ventilated in our insti-
tute. Factors that were associated with ICU mor-
tality were identified. The role of surgical lung
biopsy (SLB) in HSCT patients with unexplained
pulmonary infiltrates and progressive dyspnea
was also evaluated.
Patients and Methods
Patient population
Between August 1994 and April 2005, HSCT 
recipients who were mechanically ventilated and
admitted to the medical ICU of Linkou Chang-
Gung Memorial Hospital were enrolled. There
were 154 patients who underwent HSCT in our
institute during the study period. Fifty-two patients
were mechanically ventilated and 41 of these pa-
tients were admitted to the ICU. Six patients de-
clined ICU admission (declined by their families)
and five patients died too quickly to be admitted
to the ICU. For patients with more than one ICU
admission during the study period, only data from
the first episode were collected for analysis. The
medical records of these patients were reviewed in
detail. We collected the data on the 1st day of ICU
stay, including patients’ age and gender, the date
of transplantation, type of transplantation (autol-
ogous or allogeneic), source of stem cells (bone
marrow or peripheral blood stem cells), hemody-
namic status, and renal and hepatic function. The
acute physiology and chronic health evaluation
(APACHE) II score was tcalculated for each patien
within the first 24 hours of ICU admission. The
tstatus of discharge and date of death or last contac
twere also recorded. For patients who underwen
SLB, the results of pathologic reports, com-
tplications of the surgical procedure, and treatmen
change after SLB were also recorded. Mechanical
ventilation was defined as endotracheal intubation
with positive-pressure ventilation. Hepatic failure
was defined as a total serum bilirubin level of more
than 4 mg/dL,8 and acute renal failure, an eleva-
tion of serum creatinine level L more than 1 mg/d
from the baseline value. Acute respiratory distress
syndrome (ARDS) was defined as when patients
presented with acute-onset bilateral diffuse pul-
monary infiltrates, a pulmonary artery wedge pres-
sure less than 18 mmHg, and a PaO2/FiO2 ratio
less than 200. Any patient who required vaso-
pressor infusion, such as dopamine of > 5 μg/kg/
minute, or any use of norepinephrine on admis-
ksion to the ICU was classified as being in shoc
status.
Statistical analysis
Data were analyzed using SPSS 13.0 (SPSS Inc.,
Chicago, IL, USA). The characteristics between ICU
survivors and nonsurvivors were compared with
Fisher’s exact test for categorical variables, and
Mann–Whitney U test for continuous variables.
All tests were two-tailed, and a p value less than
0.05 was considered statistically significant.
Results
Patient characteristics
The baseline characteristics of the HSCT patients
admitted to the ICU are shown in Table 1. The
diseases for transplantation in these 41 patients
included acute leukemia (n = c17, 41.5%), chroni
myeloid leukemia (n = 12, 29.3%), lymphoma
(n=6, 14.6%), severe aplastic anemia (n=3, 7.3%),
myelodysplastic syndrome (n=2, 4.9%), and mul-
tiple myeloma (n = 1, 2.4%). Mean age was 32.7
years at the time of ICU admission. Thirty of these
41 patients (73.2%) were men. The sources of the
stem cells were bone marrow (n = 12, 29.3%) and
peripheral blood stem cell (n = 29, 70.7%). Six
patients (14.6%) underwent autologous stem cell
transplantation, and the other 35 (85.4%) were
allogeneic recipients, either from HLA-matched
nonidentical siblings (n = 29) or from HLA-
matched unrelated donors (n = 6). Thirty-four
(82.9%) patients received TBI as part of the con-
ditioning regimen.
Survival outcome
ICU mortality rate of the mechanically ventilated
HSCT recipients was high in this study. Eight 
patients (19.5%) survived the first episode of
ICU admission and seven (17.1%) ICU survivors
lived to hospital discharge. Only three of them
(7.3%) remained alive for 2 years after the first ICU
discharge. The causes of ICU mortality included
bacterial pneumonia (n = 11), cytomegalovirus
(CMV) pneumonia (n = 7), diffuse alveolar hem-
orrhage (n = 4), blood stream sepsis (n = 3), as-
pergillosis (n=3), massive hemoptysis (n= V2), RS
viral pneumonia (n = 1), CMV pneumonia com-
bined with Pneumocystitis carinii pneumonia (PCP)
(n=1), and PCP (n = 1).
Factors associated with ICU mortality
Table 1 compares the characteristics between sur-
vivors and nonsurvivors. The age at transplantation
of the survivors was significantly younger than
fICU mortality o  HSCT recipients
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Table 1. Characteristics of survivors and nonsurvivors*
Total Survivor Nonsurvivor
p
(n = 41) (n = 8) (n = 33)
Age at transplantation (yr) 32.1 ± 8.8 25.3 ± 8.2 33.8 ± 8.3 0.018
Age at ICU (yr) 32.7 ± 8.8 26.0 ± 8.0 34.3 ± 8.3 0.024
Transplantation to intubation (d) 189.4 ± 174.8 250.4 ± 238.1 174.7 ± 156.9 0.487
Male gender 30 (73.2) 5 (62.5) 25 (75.8) 0.658
Cell source 1.0
Bone marrow 12 (29.3) 2 (25) 10 (30.3)
Peripheral blood stem cell 29 (70.7) 6 (75) 23 (69.7)
Donor 1.0
Autologous 6 (14.6) 1 (12.5) 5 (15.2)
Allogeneic 35 (85.4) 7 (87.5) 28 (84.8)
TBI 34 (82.9) 7 (87.5) 27 (81.8) 1.0
APACHE II score 26.0 ± 8.7 16.0 ± 5.4 28.4 ± 7.6 < 0.001
APACHE II score ≥ 25 22 (53.7) 0 22 (66.7) 0.001
ARDS 22 (53.7) 4 (50) 18 (54.5) 1.0
Shock 15 (36.6) 0 15 (45.5) 0.018
Acute renal failure 12 (29.3) 0 12 (36.4) 0.079
Hepatic failure 12 (29.3) 1 (12.5) 11 (33.3) 0.398
Upper gastrointestinal bleeding 9 (22) 1 (12.5) 8 (24.2) 0.659
Mean arterial blood pressure (mmHg) 88.7 ± 22.5 99 ± 14.3 86.2 ± 23.5 0.067
Respiratory rate (/min) 28.1 ± 8.4 22.1 ± 9 30.2 ± 7.9 0.029
Heart rate (/min) 128.2 ± 25.8 105.3 ± 26.1 133.8 ± 22.8 0.001
*Data presented as number (%) of patients or mean ± standard deviation. TBI = total body irradiation; APACHE = acute physiology
and chronic health evaluation; ARDS = acute respiratory distress syndrome.
that of nonsurvivors (25.3 vs. 33.8 years, p=0.018).
The age of the patients on admission to the ICU
was also significantly older in the nonsurvivors
(26.0 vs. 34.3 years, p = 0.024). The duration be-
tween HSCT and endotracheal intubation in ICU
survivors seemed to be longer than the nonsur-
vivors, but the difference between the two groups
was not significant statistically. Mean APACHE II
scores of the survivors were lower than nonsur-
vivors (16.0 vs. 28.4, p<0.001), and none of the
survivors had an APACHE II score higher than 25
(p = 0.001). No survivor was in shock status or had
acute renal failure at the time of ICU admission.
Twelve patients (29.3%) had hepatic failure and
only one patient survived the ICU discharge. One
of nine patients with upper gastrointestinal (UGI)
bleeding at the time of ICU admission survived
in the ICU but was not discharged from the hos-
pital alive. Higher respiratory rate (22.1 vs. 30.2,
p=0.029) and heart rate (105.3 vs. 133.8, p=0.001)
at the time of ICU arrival were significantly asso-
ciated with ICU mortality. The differences of other
factors including gender, source of stem cells,
donors, TBI, and ARDS between survivors and non-
survivors were not statistically different.
SLB
Ten patients underwent SLB because of progres-
sive dyspnea and bilateral diffuse unexplained
tpulmonary infiltrates. Seven patients underwen
video-assisted thoracoscopic surgery (VATS), and
gthe other three patients underwent open lun
tbiopsy (OLB). One patient was in shock status a
cICU arrival and none of these patients had hepati
failure, acute renal failure, or UGI bleeding. Mean
trespiratory rate was 26.1/minute and mean hear
rate was 117.5/minute initially. All of these 10
patients received bronchoalveolar lavage (BAL)
before SLB and four had specific findings consis-
tent with PCP, CMV pneumonia, aspiration pneu-
monia, or pulmonary hemorrhage. Five of these
10 SLB patients lived to ICU discharge.
The results of surgical lung biopsies are shown
cin Table 2. Five patients had specific pathologi
findings consistent with PCP (n = 2), CMV pneu-
monia (n = 1), aspergillosis (n = 1) and aspiration
pneumonia (n = 1). Nonspecific pathologic find-
ings of SLB in the other five patients included
diffuse alveolar damage (n = 2), organizing pneu-
monia (n = 1), pulmonary hemorrhage (n = 1) and
marked fibrinous adhesion of pleura (n = 1). Five
T.M. Yang, et al
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Table 2. Results of surgical lung biopsy (SLB)
BAL finding Biopsy Pathologic
Treatment Procedure-
ICU 
Patient change Complication related
    
before SLB method finding
after SLB mortality
mortality
1 PCP OLB PCP and DAD Pulse therapy − − +
2 CMV VATS CMV pneumonia − − − −
3 Bacterial culture VATS Aspiration − Pneumothorax − +
positive pneumonia
4 Nondiagnostic VATS Aspergillosis − − − +
5 Nondiagnostic VATS Organizing Add antibiotic − − −
pneumonia
6 Iron stain OLB Pulmonary − Rapid deterioration + +
positive hemorrhage of septic shock
7 Nondiagnostic VATS DAD Pulse therapy Pneumomediastinum − +
8 Nondiagnostic VATS DAD Pulse therapy − − −
9 Nondiagnostic OLB Marked fibrinous − − − −
adhesion of pleura
10 Nondiagnostic VATS PCP Add antibiotic − − −
BAL = bronchoalveolar lavage; PCP = Pneumocystitis carinii pneumonia; OLB = open lung biopsy; DAD = diffuse alveolar damage; CMV = cytomegalovirus;
VATS = video-assisted thoracoscopic lung biopsy.
patients had changes in their treatment after SLB,
including steroid pulse therapy in three patients,
antibiotic adjustment in another patient, and ad-
ministration of treatment for PCP in the other pa-
tient. Three patients had complications from SLB,
which included pneumothorax, pneumomediasti-
num, and rapid deterioration of septic shock. One
patient died within 6 hours after the procedure
because of rapid deterioration of septic shock and
was classified as a fatal complication of SLB.
Discussion
The prevalence of respiratory failure requiring
mechanical ventilation in HSCT recipients varied
from 16% to 29% in previous studies.9–14 A total
of 154 patients received HSCT in our institution
during the study period and 52 (33.8%) had res-
piratory failure. Forty-one patients were admit-
ted to the ICU and ventilated mechanically.
Eight (19.5%) of them survived the ICU stays;
the survival rate was similar to the 16–26% of re-
cent studies.11,15–17 Six patients’ families declined
ICU admission and five patients died too quickly
to be admitted to the ICU. The aim of this study
was to evaluate the impact of intensive care on
the mortality of mechanically ventilated HSCT
recipients and to identify the factors that were
associated with ICU mortality. Therefore, those
without ICU stay were excluded in this study.
There are still controversies over the association
of age of HSCT recipients or the source of stem
cells with ICU mortality. Faber-Langendoen et al
reported that a patient’s age was predictive of
survival.9 However, Khassawneh et al found that
the age of ICU survivors and nonsurvivors was not
significantly different in mechanically ventilated
peripheral blood stem cell transplantation (PBSCT)
recipients.8 Patients’ age at transplantation was
higher in nonsurvivors in our study. The age at ICU
admission was also higher in nonsurvivors. Faber-
Langendoen et al indicated that ICU survival was
not predicted by the type of graft.9 Nevertheless,
Price and coworkers11 found that PBSCT recipients
with respiratory failure had a better survival rate
than those who had undergone conventional bone
marrow transplantation (BMT). There was no sig-
Tnificant difference in ICU mortality between PBSC
and BMT recipients in this work.
Elevated heart rate and elevated respiratory rate
are associated with ICU mortality.11 yOur stud
yshowed that rapid heart rate, rapid respirator
rate at ICU arrival, and higher APACHE II score in
mechanically ventilated HSCT patients were asso-
ciated with ICU mortality. Shemie18 treported tha
the outcome of BMT patients in the ICU was re-
tlated to multiorgan failure rather than the fac
that they are BMT patients per se. Paz et al19 and
Shorr et al15 found that the APACHE II score was
 significantly lower in ICU survivors, but Afessa
et al13 indicated that APACHE II score underesti-
mated the mortality. In this study, mean APACHE
II score was higher in nonsurvivors (28.4 ± 7.6 vs.
16.0 ± 5.4, p < 0.001) and all of the survivors had
tAPACHE II scores lower than 25, indicating tha
rlower APACHE II score is predictive of a bette
prognosis in this patient group.20
fRubenfeld and Crawford found that none o
the HSCT patients survived with lung injury com-
bined with hemodynamic instability.17 Mean ar-
rterial blood pressure of ICU survivors was highe
than that of the nonsurvivors in our study, but the
difference was not statistically significant. Mean
carterial pressure was affected by the use of inotropi
agents in patients who presented with shock in
the ICU. Therefore, the difference in mean arterial
blood pressure between ICU survivors and non-
survivors was not significantly different. Acute
renal failure, hepatic failure, and concurrent gas-
trointestinal bleeding were associated with ICU
mortality.11,17 All patients with acute renal failure
at the time of ICU admission did not survive the
ICU episode in this study, but the difference be-
tween survivors and nonsurvivors was not statis-
tically significant because of the small sample
size. One of 12 patients with hepatic failure and
one of nine with UGI bleeding survived the ICU
episode, but none of them lived to hospital dis-
ycharge. Our study showed a high rate of mortalit
associated with acute renal failure, hepatic failure,
and UGI bleeding in mechanically ventilated
fICU mortality o  HSCT recipients
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HSCT recipients, but it was not statistically 
significant.
SLB was a useful procedure in selected patients
with early-stage ARDS and the safety was accept-
able.21 It has been reported that SLB leads to
treatment change in 40% of HSCT patients with
unexplained pulmonary infiltrates and was associ-
ated with a complication rate of 11%.22 Afessa et al
reported that OLB was helpful in making specific
diagnosis but did not improve survival.13 On the
other hand, Zihlif et al indicated that a specific
diagnosis was more likely to lead to a change in
therapy and was associated with a better outcome
than a nonspecific finding.22 Ten of our patients
underwent SLB because of progressive dyspnea
and bilateral unexplained pulmonary infiltrates,
and five of them had specific pathologic diagnoses.
All of these 10 patients received bronchoscopic
BAL before SLB, and SLB was performed before the
BAL data were available. Five patients had changes
in treatment after SLB and three of them under-
went high-dose steroid therapy for the pathologic
finding of diffuse alveolar damage. Most mechan-
ically ventilated HSCT recipients with unexplained
pulmonary infiltrates and progressive dyspnea in
our ICU underwent empiric therapies for PCP,
CMV pneumonia, and fungal infections, which
were commonly found by SLB. Therefore, there
was no difference in the rate of treatment change
between patients with specific pathologic diag-
nosis and nonspecific pathologic findings. Three
patients (30%) had complications associated with
SLB, and one of them died from the fatal compli-
cation. Five (50%) of 10 SLB patients survived to
hospital discharge, all with APACHE II scores not
greater than 18 at ICU admission; lower severity
might partly contribute to their better survival.
The ICU mortality between those with specific or
nonspecific pathologic diagnosis was not signifi-
cantly different. SLB provided precise diagnosis of
unexplained pulmonary infiltrates and led to
treatment changes in a portion of mechanically
ventilated HSCT patients without significant im-
provement in survival.
In conclusion, the ICU mortality rate of me-
chanically ventilated HSCT patients was high.
gPatients with older age, presence of shock requirin
vasopressors, higher APACHE II score, and rapid
heart or respiratory rate were associated with ICU
mortality. Acute renal failure, acute hepatic fail-
ure, and UGI bleeding might also be associated
twith lower ICU survival rate, although it was no
rstatistically significant in our study. Expected poo
outcome should be presented to HSCT patients
who are critically ill and to their families for the
decision about using life-sustaining modalities.
TSLB might provide a specific diagnosis in HSC
patients with unexplained pulmonary infiltrates
tand result in changes in therapy, but the benefi
of the SLB in this patient group remained unsat-
isfactory in this work.
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